Trinity Biotech (TRIB) has released an update.
Trinity Biotech plc has reported successful pre-pivotal trial results for its innovative continuous glucose monitor (CGM) technology following its acquisition of Waveform Technologies’ assets. This new CGM system boasts enhanced accuracy, a user-friendly modular design, and cost-effective operation aimed at revolutionizing diabetes management. With the positive trial outcomes, Trinity Biotech is moving forward with further trials, setting the stage for a pivotal trial in 2025, and aims to capture a significant share of the rapidly growing CGM market.
For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.
